CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company of